
CERo Therapeutics, Inc.: A pioneering cell therapy firm integrating innate and adaptive programs to combat disease.
Founded with a mission to revolutionize cancer treatment, CERo Therapeutics, Inc. is a pioneering cell therapy company focused on integrating innate and adaptive immune responses into single T cells to combat disease. The company's core vision is to discover, translate, and deliver curative cell therapies that enhance tumor clearance. Their innovative CER T-cell platform aims to exploit natural immune processes, offering novel approaches for the treatment of various cancers.
CERo Therapeutics has attracted notable investors and industry leaders who support its groundbreaking work in cellular immunotherapy. The company has made significant strides in advancing its CER T-cell platform, positioning itself as a key player in the biotech sector. By reimagining tumor cell clearance, CERo Therapeutics is making a substantial impact on the development of next-generation cancer treatments.

Cellerant Therapeutics

Ernexa Therapeutics
eternatx.com

Cellular Approaches

Cell BioEngines
cellbioengines.com

Cello Therapeutics
cellothera.com

Celsius Therapeutics
celsiustx.com

Century Therapeutics
centurytx.com

A2 Biotherapeutics
a2bio.com
CyThera

Luminary Therapeutics
luminarytx.com

Inceptor Bio
inceptor.bio

Celularity
celularity.com

Cellevolve Bio
cellevolve.com

Tr1x
tr1x.bio

Kyverna Therapeutics
Companies similar to CERo Therapeutics include Cellerant Therapeutics, Ernexa Therapeutics, Cellular Approaches and Cell BioEngines.
CERo Therapeutics was founded in 2017.
CERo Therapeutics' headquarters is located in South San Francisco, CA, US.
CERo Therapeutics' most recent funding round was for $40M (USD) in March 2020.
As of Mar 18, 2020, CERo Therapeutics has raised a total of $41.4M (USD).
CERo Therapeutics has 13 employees as of Feb 5, 2024.